#United States #Washington D.C. #Medical Device #Section 232 #AOM Advisors

New White Paper Discussing the Future of the U.S. Medical Device Sector

In an era where healthcare supply chains are crucial, a significant white paper has been released by Antonio Ortiz-Mena, CEO of AOM Advisors, and Christopher G. Sheeron, CEO of Action for Health. Published on April 14, 2026, this document entitled "Critical Care: Protecting U.S. Medical Device Leadership Through Targeted Section 232 Action" offers a thorough analysis for U.S. policymakers as they approach a pivotal decision concerning the Section 232 national security investigation into medical device imports.

The timing of this report is pivotal for the medical device industry, which commands an impressive $280 billion in revenue and is responsible for the employment of 2.8 million Americans. The U.S. currently holds a dominating 40% share of the global market, emphasizing the sector's importance in the broader healthcare landscape. Following a Supreme Court ruling that invalidated certain tariffs, Section 232 has emerged as the primary tool for implementing protective measures within this sector.

Recognizing Industry Strengths

Ortiz-Mena emphasizes, "The medical device sector is an American powerhouse where 70% of technology sold in the U.S. is already produced across 16,000 facilities domestically." The essence of the new proposal under Section 232 is not about rebuilding from the ground up but about strategically reinforcing the existing capabilities without jeopardizing healthcare access for providers and patients alike.

Strategic Tariff Implementation

This white paper proposes a two-tier approach to applying tariffs, which is critical due to the potential effects such actions could have on the healthcare system:
1. Tier 1 Immediate Action: This involves the application of tariffs on Personal Protective Equipment (PPE), as the domestic production capacity is primed for scaling up supply.
2. Tier 2 Conditional Implementation: This suggests that tariffs on essential consumables and complex diagnostics should depend on the demonstration of expanded domestic capacity to avoid creating critical shortages in healthcare supplies.

While some may fear that tariffs may lead to increased costs for patients due to economic pressures on hospitals—especially when Medicare reimbursement is only 83 cents per dollar—Ortiz-Mena and Sheeron warn that poorly implemented tariffs could destabilize the already delicate supply chain system.

The Role of Supply Chains

The report also addresses vulnerabilities within non-allied supply chains, pinpointing the Tijuana–San Diego corridor, known as North America's largest medical device cluster, as a key ally in strengthening U.S. supply chains. By applying pressure to uncertain supply chains originating from adversarial nations while safeguarding goods under the USMCA agreement, policymakers can facilitate the process of reshoring essential production.

Key Findings of the White Paper

The paper's findings highlight several essential aspects of the medical device industry:

• - Market Leadership: The U.S. holds a commanding 40% share of the global medical device market.
• - Domestic Resilience: Seventy percent of medical technology used within the U.S. is produced domestically.
• - Economic Risk: Even minor supply cost fluctuations can lead to substantial margin impacts for major hospital systems.
• - Strategic Reshoring: Mexico has risen to become the leading exporter of medical devices to the U.S. as production shifts away from China.

With detailed policy recommendations and economic modeling included, this white paper serves as an urgent call to action for policymakers aimed at preserving U.S. leadership in the medical device sector. For those interested in further details, the full report is accessible through Action for Health's channels.

Action for Health is dedicated to advocating for equitable healthcare outcomes and enhancing public understanding of significant healthcare policies, laws, and regulations critical to patients across the nation.